Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure Glaucoma
Study Details
Study Description
Brief Summary
A multicenter, parallel, open, non-inferior randomized controlled trial was conducted to compare the effectiveness and safety of phacotrabeculectomy and phacogoniotomy in the treatment of advanced primary angle closure glaucoma, so as to provide a better surgical alternative.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Glaucoma is the leading cause of irreversible blindness worldwide, and primary angle closure glaucoma (PACG) accounted for the majority particularly in Asia and China. The preferred treatment method is anti-glaucoma surgery-trabeculectomy (Trab) combined with lens extraction. Phacotrabeculectomy has become the first-line choice of anti-glaucoma suregery in the treatment of advanced PACG. However, it was not an ideal method due to the bleb-related complications and troublesome postoperative nursing, as well as the difficulty for surgeons, caused by trabeculectomy. However, recent studies revealed that the phacoemulsification with intraocular lens implantation (PEI) combined with goniosynechialysis (GSL) has achieved efficacy in the treatment of PACG.
With the advent of minimally invasive glaucoma surgeries (MIGS), there is an increasing number studies indicating the MIGS performed great efficacy in the treatment of primary open angle glaucoma. While,there were a few small-sampled retrospective studies which showed therapeutic effects in PACG. The GSL plus goniotomy (GT) could achieve great efficacy in lowering the intraocular pressure of PACG patients. However, there is still a lack of high quality and high-level randomized controlled trials.
Therefore, this study intends to conduct a multicenter, parallel, open, non-inferior randomized controlled trial to compare the effectiveness and safety of PEI+ Trab and PEI+GSL+GT in the treatment of advanced PACG, so as to provide a better surgical treatment for PACG.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: PEI+GSL+GT Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy. |
Procedure: phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy
The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
|
| Experimental: PEI+Trab Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with trabeculectomy. |
Procedure: phacoemulsification with intraocular lens implantation combined with trabeculectomy
The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.
|
Outcome Measures
Primary Outcome Measures
- Mean change of intraocular pressure [Postoperative 12, 24, 36 months.]
Change from baseline IOP after surgery using Goldmann or non-contact tonometer.
Secondary Outcome Measures
- Cumulative success rate of surgery [12, 24, 36 months]
(i) Complete success is defined as the postoperative IOP between 5 and 18 mmHg, and 20% reduction from baseline with no need for IOP-lowering medication. (ii) Qualified success is defined as the postoperative IOP between 5 and 18 mmHg, and 20% reduction from baseline with or without IOP-lowering medication.
- Intraoperative and postoperative complications [0, 1, 7 day. 1, 3, 6, 12, 18, 24, 30, 36 months]
For example, shallow anterior chamber, hyphema, persistent hypotony, corneal endothelium decompensation, endophthalmitis, and other filtering bleb-related complications.
- Anti-glaucomatous medications [0, 1, 7 day. 1, 3, 6, 12, 18, 24, 30, 36 months]
Numbers and types of anti-glaucomatous medications
Other Outcome Measures
- Visual acuity [0, 1, 7 day. 1, 3, 6, 12, 18, 24, 30, 36 months]
Uncorrected and best corrected visual acuity will be documented using ETDRS chart.
- Degree of peripheral anterior synechia [3, 12, 24, 36 months]
The peripheral anterior synechia is checked using gonioscopy.
- Corneal endothelial cell counting [0, 12, 24, 36 months]
Corneal endothelial cell counting will be documented using specular microscope.
- Visual field [0, 12, 24, 36 months]
Visual field examination is performed using Humphrey analyzer.
- Optic nerve head morphology and retinal parameters [0, 12, 24, 36 months]
Optic nerve head morphology and retinal parameters based on optical coherence tomography (Cirrus 5000, Zeiss, CA, USA or Spectralis, Heidelberg, Germany)
- Measurement of quality of life [0, 12, 24, 36 months]
Quality of life is measured with EQ-5D-5L questionnaire.
- Filtering bleb classification [12, 24, 36 months]
Filtering bleb classification based on Indiana Bleb Appearance Grading Scale
- Time-consuming of operation and the surgery cost [1 day]
Time-consuming of operation and the surgery cost are based on the electronic healthy system.
Eligibility Criteria
Criteria
- Inclusion criteria
-
Aged 40-80 years;
-
Diagnosed with advanced PACG: meet with (1) (2) (3) or (1) (2) (4)
-
At least 180-degree PAS under gonioscopy and it should cover the nasal and inferior quadrants for surgical purposes;
-
IOP >21 mmHg with or without anti-glaucoma medication;
-
Obvious glaucomatous optic neuropathy (cup-to-disc [C/D] ratio≥0.7, or C/D asymmetry > 0.2, or the rim width at the superior and inferior temporal < 0.1 vertical diameters of optic disc);
-
With glaucomatous visual field defects, such as nasal step, arcuate scotoma, and paracentral scotoma on a reliable Humphrey analyzer using SITA-Standard 24-2 or 30-2 algorithm; mean deviation ≤ -12dB;
-
Clinically obvious cataract and uncorrected visual acuity (UCVA) <0.63 (Early Treatment Diabetic Retinopathy Study, [ETDRS] chart), or need lens extraction assessed by a clinician;
-
Voluntarily participate in study and provide signed informed consent.
- Exclusion criteria a. History of ocular surgery (other than laser iridotomy or laser iriplasty) or trauma; b. With other types of glaucoma; (i.e. open angle glaucoma, secondary angle-closure glaucoma, steroidal glaucoma, angle regression glaucoma, neovascular glaucoma, nanophthalmos, pseudoexfoliation syndrome) c. The International Standardized Ratio > 3.0 for patients receiving warfarin or anticoagulant therapy before surgery; d. With retinal disease that affects the collection of ocular parameters; f. Monophthalmia (best-corrected visual acuity [BCVA] <0.01 in the non-study eye); g. With other serious systemic diseases; h. Pregnant or lactating women * If both eyes are eligible for the study, the eye with the worse UCVA will be recruited.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Zhongshan Ophthalmic Center | Guangzhou | Guangdong | China | |
| 2 | Zhongshan Ophthalmic Center | Guangdong | China |
Sponsors and Collaborators
- Sun Yat-sen University
- The Second Affiliated Hospital of Harbin Medical University
- West China Hospital
- First Hospital of Shijiazhuang City
- Union hospital of Fujian Medical University
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Handan City Eye Hospital
- The Third Affiliated Hospital of Chongqing Medical University
Investigators
- Principal Investigator: Xiulan Zhang, MD, PhD, Zhongshan Ophthalmic Center, Sun Yat-sen University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021KYPJ090